News & Announcements
-
Placing and Broker Option
/**/ RNS Number : 0116E IQ-AI Limited 22 February 2024 IQ-AI Limited (“IQ-AI” or the “Company”) Placing and Broker Option IQAI Limited (the “Company” or “IQAI”), the parent company of Wisconsin-based Imaging Biometrics, LLC (“IB”), which is focused on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively,
-
FDA Application Update
/**/ RNS Number : 6911C IQ-AI Limited 09 February 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) FDA Application Update Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), reports that it will modify and resubmit its application for Pediatric Rare Disease (PRD) Designation, in response to a letter from
-
IB awarded a $100,000 grant
/**/ RNS Number : 8587B IQ-AI Limited 02 February 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) IB awarded a $100,000 grant by the Musella Foundation Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), announces that it has been awarded a $100,000 grant by the Musella Foundation For Brain
-
Holding(s) in Company
/**/ RNS Number : 4625A IQ-AI Limited 22 January 2024 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to
-
Director Dealings and Conversion of CLNs
/**/ RNS Number : 6148Z IQ-AI Limited 15 January 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) Director Dealings and Conversion of Convertible Loan Notes IQ-AI Ltd has received convertible loan note conversion notices from Trevor Brown, the CEO of IQ-AI, and Micheal Schmainda, a director of IQ-AI. Trevor Brown is converting a total